Senior Vice President at ASLAN Pharmaceuticals and Chief Medical Officer at Carrick Therapeutics. Dr. Barge was trained in medicine at Oxford and London, and specialised in haematology and oncology. As former VP Oncology and Infection at AstraZeneca, Dr. Barge has great oncology drug development experience. Before joining AstraZeneca, Dr. Barge spent 8 years at Amgen as European Medical Director.
Scientific Director of Princess Máxima Center for pediatric oncology, Past President of the Royal Netherlands Academy of Sciences and former Director of the Hubrecht Institute, The Dutch Institute for Developmental Biology (KNAW) in Utrecht. Prof. Clevers is author of over 540 scientific papers and recipient of many prestige’s international awards.
Founder of Biopharma Excellence, EUCRAF and Pharmatching.com. Dr. Dallmann has over 25 years of experience in facilitating drug development and is an expert in the field of Regulatory Affairs, having worked amongst others at Committees of the European Medicines Agency (EMA) and at the German Paul-Ehrlich-Institut. Dr.Dallmann is biologist by training with a PhD in immunology from Berlin University (Charité).
Stef van Doesburg
Managing Partner Greenfield Capital Partners. Having completed over 30 M&A transactions, Mr. van Doesburg has extensive experience in the private equity sector, at both national and international level. Before joining Greenfield, Mr. van Doesburg worked as senior manager corporate finance at Price Waterhouse in both Amsterdam and London.
Prof. Gerritsen is medical oncologist at the Radboud Medical Center Nijmegen and is former Director of the Cancer Center Amsterdam/VUMC. He has extensive expertise in translational research with a special interest in tumor-immunology. Prof. Gerritsen achieved his PhD in 1989 at the Medical School of the Erasmus University of Rotterdam, where after he worked in different positions at Memorial Sloan Kettering Cancer Center in New York, the University Hospital Utrecht, and The Netherlands Cancer Institute Amsterdam.
Prof. of Cancer Medicine, Univ. of Oxford, and Prof. of Medicine, Weil-Cornell College of Med, New York, former President, European Society of Medical Oncology. David has an international reputation for treatment of and research into colorectal cancer.
Prof. Melief is CSO of ISA Pharmaceuticals in Leiden, The Netherlands. Before becoming CSO of ISA, Prof. Kees Melief was Head of the Department Immunohematology and Bloodbank of the University Hospital in Leiden and Professor of Internal Medicine. Prof. Melief is a board member and advisor of multiple organizations and companies and is considered one of the world’s most renown tumor immunologists.
(Co-)founder of companies like Oncomethylome, Pluriomics and NCardia. He has over 40 years of experience in the pharmaceutical and biotech industry in Europe and the U.S. He served on multiple boards and in various executive positions. Throughout his career, Herman Spolders has been instrumental in starting and growing biotech companies, IPO’s, forging large pharma-biotech collaborations, defining new product opportunities with a focus on clinical diagnostics for cancer or infectious diseases. He studied biochemistry at the University of Amsterdam and graduated at INSEAD.
Jan van de Winkel
CEO of biotech company Genmab and professor of Immunology at the UMC Utrecht. Prof. Van de Winkel is renowned for his work on the biological role and clinical application of antibodies. Prof. Van de Winkel has over 20 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. Prof. Van de Winkel holds a professorship in Immunology at Utrecht University and is board member of several biotech companies.
Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer
InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting